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Abstract
Deep Brain Stimulation (DBS) of the Subthalamic Nucleus (STN) improves motor symptoms in Parkinson’s disease (PD), but
can exert detrimental effects on impulsivity. These effects are especially related to the inability to slow down when high-
conflict choices have to be made. However, the influence that DBS has on delay aversion is still under-investigated. Here, we
tested a group of 21 PD patients on and off stimulation (off medication) by using the Cambridge Gamble Task (CGT), a
computerized task that allows the investigation of risk-related behaviours and delay aversion, and psychological
questionnaires such as the Barratt Impulsiveness Scale (BIS), the Sensitivity to Punishment and to Reward Questionnaire
(SPSRQ), and the Quick Delay Questionnaire (QDQ). We found that delay aversion scores on the CGT were no higher when
patients were on stimulation as compared to when they were off stimulation. In contrast, PD patients reported feeling more
impulsive in the off stimulation state, as revealed by significantly higher scores on the BIS. Higher scores on the sensitivity to
punishment subscale of the SPSRQ highlighted that possible punishments influence patients’ behaviours more than
possible rewards. Significant correlations between delay aversion scores on the CGT and QDQ delay aversion subscale
suggest that these two instruments can be used in synergy to reach a convergent validity. In conclusion, our results show
that not all impulsivities are detrimentally affected by DBS of the STN and that the joint use of experimental paradigms and
psychological questionnaires can provide useful insights in the study of impulsivity.
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Introduction
Deep Brain Stimulation (DBS) of the Subthalamic Nucleus
(STN) represents a therapeutic advance for severely disabled
patients with Parkinson’s disease (PD) [1,2,3,4,5]; it inhibits hyper-
activation of the STN, therefore acting as a reversible lesion of the
target areas. STN-DBS is efficacious on motor symptoms [1,2,3,4]
and enables the reduction of dopaminergic treatment [6].
Moreover, DBS can be considered globally safe in terms of
cognitive outcomes both in the short [1,7,8] and long term
[6,9,10], even though single patients may develop a clinically
relevant cognitive decline [11]. Although some investigators have
shown that STN-DBS can reduce impulsive behaviours
[12,13,14,15,16,17], others have reported detrimental effects of
DBS [15,18,19], see [20] for a review. Risk factors for the
development of post-surgery impulsive behaviours include pre-
morbid susceptibility [20], but the exacerbation of an impulsive
symptomatology may also derive from the progress of the
pathology and from DBS itself [21,22]. Studies conducted with
the use of self-administered questionnaires, such as the Baratt
Impulsiveness Scale (BIS), have shown that STN-DBS treated
patients feel more impulsive than patients receiving only medical
therapy [18]. However, self-administered questionnaires may be
susceptible to subjective over- or under-estimations of the severity
of the symptomatology [23,24]. Thus the results of such
questionnaires, where possible, should always be compared to
those of experimental paradigms to reach a convergent validity.
Experimental paradigms can provide greater sensitivity to study
impulsivity [22]. For instance, it has been documented that, as
compared to the off stimulation condition, PD patients on
stimulation have a poorer performance in go/no-go tasks
[25,26,27], stop signal tasks [28] and fail to slow down in selecting
responses in a high-conflict context [29,30,31]. Importantly, the
concept of impulsivity is not unitary - indeed, impulsive behaviours
reflect the inability to use externally available information to
reflect and ponder future actions and their consequences (cognitive
impulsivity); the inability to opt for larger, delayed rewards rather
than smaller, immediate ones (delay aversion), and impairment in
suppressing prepotent motor responses (motor impulsivity/impul-
sive action) [32]. These different aspects of impulsivity are
dissociable at both the neuroanatomical and neuropharmacolog-
ical levels [33,34]. Preclinical models have demonstrated that
lesions of the STN have opposing behavioural effects on different
aspects of impulsivity (see [33]). Although the effects of STN-DBS
on cognitive and motor impulsivity have been explored
[25,26,29,31,35], experimental evidence on the effects of DBS
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on delay aversion is still lacking. Interestingly, preclinical studies
suggest that lesions to the STN may even improve delay aversion
in rats [36].
Here, we first investigated the effect of STN-DBS on delay
aversion in patients on stable DBS stimulation by using the
Cambridge Gamble Task (CGT) [37], a computerized task for the
assessment of delay aversion, and psychological questionnaires.
We then investigated the possible short-term effects of DBS on self-
reported measures of impulsivity, comparing psychological ques-
tionnaire scores between the off and on stimulation conditions.
Materials and Methods
Patients
This study was approved by the Department of Psychology,
University of Turin Ethical Committee and all participants gave
their written informed consent. Twenty-one PD patients partic-
ipated in this study (8 women). Of these, thirteen completed the
entire battery composed of the CGT [37] and the psychological
questionnaires (Barratt Impulsiveness Scale, BIS, Italian version
[38], the Sensitivity to Reward and Sensitivity to Punishment
Questionnaire, SRSPQ [39], the Quick Delay Questionnaire,
QDQ [40], see next paragraphs), while eight completed only the
CGT. The patients had an average age of 60 (66.2, range 48–70)
and an average 8.6 years of schooling (63.8, range 5–17). They
were evaluated at an average of 9.5 months (64.9, range 4–28)
after implantation of electrodes for DBS of the STN. This allowed
us to ensure that patients were on stable stimulation and no longer
prone to microlesive effects of the surgical procedure [10]. A post-
operative 3D CT fused with the pre-operative MRI scan was
performed to confirm successful surgery and to check the final
position of the electrodes. The patients were administered
psychological and neuropsychological assessments as clinical
routine when on stimulation and on medication. These assess-
ments were used to exclude clinically relevant psychological
symptoms and neuropsychological impairments [11]. In addition
to dopaminergic therapy, seven patients were taking antidepres-
sants (six were on serotonin-norepinephrine reuptake inhibitors
(SNRIs) and one on a selective serotonin reuptake inhibitor
(SSRI), six on benzodiazepines, five on atypical antipsychotics).
Table 1 summarizes the clinical and demographic details.
Experimental procedure
All patients performed the tasks after at least 12 hours
(overnight withdrawal) of wash-out from the habitual dopaminer-
gic therapy (off medication). The patients performed the
experimental procedure twice - ‘on stimulation’ and ‘off stimula-
tion’ - and the order of administration (with the first experimental
session either on or off stimulation) was counterbalanced across
subjects. The ‘off stimulation’ session was begun at least
40 minutes after DBS was switched off. Before the experimental
procedure was begun, a neurologist administered the UPDRS-III
to ascertain that patients were in their off condition. The ‘on
stimulation’ session, when not the initial one, was begun at least
40 minutes after stimulation was switched on. Also in this case, the
on condition was tested by the administration of the UDPRS-III.
The patients performed the task either on two separate days
(N= 3), or on the same day (one session in the morning, another in
the afternoon (N=18)). Preliminary analyses revealed that the
results obtained when the task was administered on two separate
days were no different from those obtained when it was
administered on the same day (p= 0.233). The two groups were
therefore analyzed together. In each session, the patients
performed the CGT and completed the psychological assessment,
which included the BIS, SPSRQ and QDQ. For the psychological
questionnaires, they were explicitly asked to respond according to
how they felt in the condition of stimulation that was being tested.
Cambridge Gamble Task
We used the Cambridge Gamble Task [37] to assess delay
aversion. In this task, participants are asked to choose whether a
yellow token is hidden under one of the ten blue or red boxes
arrayed on the top of the screen. The ratio of blue to red boxes
varies from 1 blue/9 red to 9 blue/1 red, thus covering all possible
combinations; the patients were told that the aim of the game was
to increase their points as much as possible. The first choice,
regarding which colour to bet on, reflects quality of decision,
namely the tendency to select most likely outcomes. The time
employed to select the most likely outcome reflects the deliberation
time. On this first choice, patients were asked to bet their points
with the goal of increasing them (more rational choices are related
to most likely outcomes of winning). The amount of points they
could bet appeared on the right-hand side of the screen after the
first selection was made. The patients placed their bets under two
different conditions: ascending and descending. With the former,
the points to bet begin with low stakes and increase, whereas with
the latter, the points start from high stakes and progressively
decrease. The points represent percentages of the total score, but
the patients are not explicitly informed of this. The participants are
invited to select a bet according to their confidence in the red/blue
box decision. An optimal strategy requires modulation of the
betting strategy that depends on the chances of winning and is
measured by risk adjustment. Delay aversion is defined as the
tendency to select always the first bets, in both ascending and
descending conditions. The higher the score, the higher the
tendency to impulsivity.
Barratt Impulsiveness Scale
The Barratt Impulsiveness Scale (BIS-11 Italian version, [38]) is
a 30-item self-administered questionnaire that measures different
aspects of impulsivity (e.g. motor impulsiveness, lack of planning,
and attentional impulsiveness). For each statement participants
have to indicate how often they think or behave as such (never/
rarely, sometimes, often, always). The BIS returns a global score of
impulsivity ranging from 30 to 120, the sum of three separate
indexes: ‘motor impulsiveness’, MI, with a score range from 11–
44 points, ‘non-planning impulsiveness’, NPI, also with a score
range from 11–44 points and ‘attentional impulsiveness’, AI, with
a score range from 8–32 points. Higher scores indicate greater
impulsivity.
Sensitivity to Reward and Sensitivity to Punishment
Questionnaire
The Sensitivity to Reward and Sensitivity to Punishment
Questionnaire (SPSRQ) [39] is a 48-item yes/no self-report
questionnaire. The SPSRQ is composed of two subscales:
Sensitivity to Punishment (SP) and Sensitivity to Reward (SR).
These reflect two behavioral systems: inhibition and approach
[41,42]. The Behavioral Inhibition System (BIS) is sensitive to
punishment and novel stimuli. It motivates the inhibition of the
performance of behaviors that can lead to future punishments and
represents a sort of ‘stop’ system, promoting avoidance behaviors.
In contrast, the Behavioral Approach System (BAS) represents the
‘go’ signal towards positive reinforcers and rewards. People with a
highly activated BAS tend to impulsivity. The score of each
subscale varies from 0–24, with higher scores indicating a higher
sensitivity to punishment or reward.
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Quick Delay Questionnaire
The Quick Delay Questionnaire (QDQ, [40]) is a 10-item self-
report questionnaire in which subjects have to declare their degree
of agreement with each statement on a five-point Likert scale. The
QDQ is composed of two subscales: delay aversion and delay
discounting. Higher scores on the delay aversion subscale indicate
the presence of positive emotions during the delay, whereas higher
scores on the delay discounting subscale indicate the tendency to
make choices leading to long-term high benefits. Both subscales
have scores ranging from 5–25 points.
Statistical analysis
Statistical analyses were performed using the software PASW
Statistics 18 (SPSS Inc.).
Data from the ascending and descending conditions of the CGT
were averaged together and analyses performed using a paired
sample t-test (2-tailed) with a significance threshold of p,0.05.
Risk adjustment scores, which include the evaluation of the betting
strategy in four conditions of stimulation (6:4, 7:3, 8:2, 9:1) were
analyzed using a repeated-measure ANOVA with the ‘stimulation’
(2 levels, on and off) and ‘bet conditions’ (4 levels, 6:4, 7:3, 8:2, 9:1)
as factors. The Hyundt-Feldt correction was used in case of
violation of sphericity [43].
Table 1. Clinical and demographic characteristics of the PD sample.
Patient code Gender Age
Years of
schooling
Months after
surgery UPDRS III on/off LEDD mg/day
Parameters of stimulation right/
left
1 F 59 17 12 24/33 1600 3.6 V; 60 msec; 130 Hz; 11-/3.4 V;
60 msec; 130 Hz; 3-
2 F 60 8 11 5.5/14 505 3.4 V; 60 msec; 130 Hz; 10-/3.3 V;
60 msec; 130 Hz; 2-
3 F 57 9 11 23/35 580.19 3.6 V; 60 msec; 130 Hz; 11-/3.6 V;
60 msec; 130 Hz; 3-
4 F 48 11 10 29/59 500 2.4 V; 60 msec; 130 Hz; 10-/2.4 V;
60 msec; 130 Hz; 1-
5 M 57 11 10 22/45.5 1180.19 3.6 V; 60 msec; 130 Hz; 8-/3.6 V; 60 msec;
130 Hz; 0-
6 F 69 5 5 15.5/22.5 771.58 3.6 V; 60 msec; 130 Hz; 10-/3.3 V;
60 msec; 130 Hz; 2-
7 M 57 10 5 23.5/43.5 750.38 3.6 V; 60 msec; 130 Hz; 9-/3.6 V; 60 msec;
130 Hz; 1-
8 M 59 5 10 36.5/49.5 500 3.6 V; 60 msec; 130 Hz: 10-/3.0 V;
60 msec; 130 Hz; 1-
9 F 60 10 7 30.5/47 625 3.0 V; 60 msec; 130 Hz; 11-/3.5 V;
60 msec; 130 Hz; 3-
10 M 64 5 4 7/36 1310 2.8 V; 60 msec; 130 Hz; 3-/3.2 V; 60 msec;
130 Hz; 7-
11 M 49 8 7 31/65 1200 3.5 V; 60 msec;130 Hz; 7-/3.2 V;
60 msec;130 Hz; 1-
12 M 58 5 6 46/73 554 3.2 V; 60 msec;130 Hz; 3-/3.2 V;
60 msec;130 Hz; 7-
13 M 67 5 11 13.5/31.5 600 3.2 V; 60 msec; 130 Hz; 4-/3 V;
60 msec;130 Hz; 1-
14 F 67 5 3 21/56.5 525.19 2.9 V; 60 msec; 130 Hz; 6-/2.7 V; 60 msec;
130 Hz; 2-
15 M 70 5 17 18.5/39.5 350.19 2.9 V; 60 msec; 130 Hz; 5-/3.0 V; 60 msec;
130 Hz; 2-
16 M 62 13 9 12/48 910 5 V; 60 msec; 80 Hz; 5-/5 V; 60 msec;
80 Hz; 1-
17 F 71 12 11 30.5/48 700.19 3.4 V; 60 msec; 130 Hz; 7-/3.2 V; 60 msec;
130 Hz; 2-
18 M 50 5 30 22.5/42 187.5 2.8 V; 60 msec; 130 Hz; 7-/3.2 V; 60 msec;
130 Hz; 3-
19 M 60 8 10 46/70 475.19 3.6 V; 60 msec; 130 Hz; 2-/3.4 V; 60 msec;
130 Hz; 7-
20 M 55 15 6 17/37.5 835 3.5 V; 60 msec; 130 Hz; 7-/3.5 V; 60 msec;
130 Hz; 3-
21 M 65 5 5 23.5/55.5 650 3.4 V; 60 msec; 185 Hz; 3-/3.6 V; 60 msec;
185 Hz; 6-
LEDD, Levodopa Equivalent Daily Dose.
doi:10.1371/journal.pone.0043261.t001
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BIS total scores were compared using a paired comparison t-test
(2-tailed). Additional comparisons were performed on each
subscale separately as maximum scores changed from one subscale
to the other. SPSR and QDQ scores were analyzed using a
repeated measure ANOVA, using as factors the ‘stimulation’ (2
levels, on and off) and the ‘scale’ (SPSRQ 2 levels, sensitivity to
punishment and sensitivity to reward; QDQ 2 levels, delay
aversion and delay discounting). These analyses were possible
since the subscales of these questionnaires have the same score
range.
The psychological questionnaire scores were correlated with
CGT scores to investigate whether a convergent validity exists
between psychological self-reports and experimental measures.
The correlations were performed separately for results in the on
and off stimulation conditions.
Results
Since the results of the CGT did not change whether 13 or 21
patients were included in the analyses, the results of the entire
sample are provided.
Cambridge Gamble Task
Delay aversion scores were no different in the ‘on’ and ‘off’
stimulation conditions (t(20) = 0.256, p = 0.800). Similarly, the
quality of decision and deliberation times were not affected by
stimulation (quality of decision, on vs off t(20) =20.253, p = 0.803;
deliberation times, on vs off, t(20) = 0.488, p = 0.631). The analysis
of the scores of risk adjustment indicated that patients placed
higher bets with more favourable ratios (main effect of ‘bet
condition’ F(2,28) = 3.615, p= 0.037), but that these choices were
not affected by the stimulation (main effect of ‘stimulation’
F(1,13) = 0.451, p = 0.514). See figure 1.
Barratt Impulsiveness Scale
The patients felt globally less impulsive when on stimulation
(t(12) = 2.680, p = 0.020). They also reported lower scores on the
AI subscale when stimulation was on (t(12) = 2.127, p= 0.055). No
differences emerged between the MI (t(12) = 1.171, p = 0.264) and
NPI (t(12) = 1.367, p= 0.197) subscales in the two stimulation
conditions.
Sensitivity to Punishment and Sensitivity to Reward
Questionnaire
The total scores on the SPSRQ were no different in the two
stimulation conditions (F(1,12) = 1.581, p = 0.233). However, both
when on and off stimulation, patients reported higher scores on the
SP subscale (F(1,12) = 6.858, p = 0.022).
Quick Delay Questionnaire
The total scores on the QDQ were no different in the two
stimulation conditions (F(1,12) = 1.990, p = 0.184). No differences
emerged in any of the subscales (DA vs DD F(1,12) = 0.073,
p = 0.792).
The results are summarized in figure 2.
Correlations between CGT and questionnaires scores
A significant negative correlation was found, in the on
stimulation condition, between delay aversion scores on the
CGT and delay aversion scores on the delay aversion subscale of
the QDQ (r =20.626 p= 0.029). That is, higher scores of delay
aversion were correlated to more negative feelings when waiting
for rewards (see figure 3).
Discussion
In the present study we aimed (i) to investigate the effects that
STN-DBS has on delay aversion in PD patients and (ii) to explore
possible short-term effects of STN-DBS on self-reported impul-
sivity. We observed two main findings: first, STN-DBS does not
worsen delay aversion; second, STN-DBS is able to induce
changes in the self-reported psychological state in the short term,
that is when switching on and off stimulation.
‘Impulsivities’ and Deep Brain Stimulation
Previous animal studies [44,45] have suggested that, in the rat,
lesions to the STN have opposite effects on behaviour: increasing
impulsive actions but reducing delay aversion [33]. So far, most of
the studies investigating motor (and cognitive) impulsivity in PD
patients have found that STN-DBS has detrimental effects on
impulsivity as measured by go/no-go tasks [25,46]. These
detrimental effects were found to be particularly related to
stimulation of the ventral subthalamic nucleus [47] and accom-
panied by changes in synaptic activity consisting in reduced
activation in the cortical networks responsible for reactive and
proactive response inhibition [25]. Moreover, PD patients under
STN-DBS have been found to increase impulsive action [48]:
STN-DBS, acting detrimentally on the ‘hyperdirect’ circuit
connecting the medial prefrontal cortex (mPF) and the STN
[49,50,51], disrupts the ability to refrain from selecting choices
without pondering (DBS). Indeed, STN stimulation was found to
diminish theta band power measured by electroencephalography
Figure 1. Summary of results on the Cambridge Gamble Task (CGT). Stimulation did not affect the performance in any of the variables of
interest. The purple bars and dashed line summarize the results in the off stimulation condition; the green bars and solid line those in the on
stimulation condition.
doi:10.1371/journal.pone.0043261.g001
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(EEG) in the mPF, which in turn was related to an adaptive
increase in response times when the decision process required
responses to high-conflict choices [30]. A recent study by
Rodriguez-Oroz and colleagues [52] has suggested that patients
showing dopaminergic side effects have, in the on state, a
characteristic oscillatory activity in the theta-alpha band at
different frequencies and with different topography if they suffer
from motor (such as dyskinesias) or behavioural side effects
(abnormal impulsivity). In contrast, such oscillatory activity does
not appear in patients without dopaminergic complications.
Our present findings suggest that STN-DBS does not worsen
delay aversion and demonstrate that also in humans not all
impulsivities are detrimentally affected by DBS of the STN. These
findings, together with the results of previous studies [53,54], also
point to the possibility that some aspects of impulsivity are more
affected by dopaminergic therapy than they are by STN-DBS. In
this regard, dissociations between the effects of medication and
stimulation have been previously documented [48,55]. In a
previous study we reported a positive linear relationship between
dopaminergic dose and degree of delay aversion [54], with
patients taking higher doses of dopaminergic medication showing
higher delay aversion scores. Thus it is likely that when
dopaminergic doses are reduced after surgery, the tendency to
delay aversion is reduced. According to this explanation, delay
aversion is more likely to arise from a dopaminergic overdose of
the ventral striatum circuit (overdose theory) [56,57]. Housden
and colleagues [58] reported a double dissociation between reward
learning and delay aversion in PD patients with and without
impulsive-compulsive disorders, thus proposing that the preference
for immediate rewards against future ones is more likely to be
underpinned by excessive dopaminergic transmission. An alterna-
tive explanation proposed to explain the differences between
betting behaviours in the on and off medication conditions states
that delay aversion as measured by the GCT reflects ‘impatience’,
that is, the inability to undergo delay without action [22]. In this
view, impatience could be favoured by different perception of time
in the two therapeutic conditions, and in particular by a
perception of time going by more slowly in the on medication
condition [55,59,60,61]. The possibility that delay aversion, as
measured by the CGT, reflects impatience is supported by the
negative correlation found between delay aversion on the CGT
and delay aversion scores on the DA subscale of the QDQ.
Indeed, higher DA scores indicate the presence of positive feelings
during delay. None of the other CGT variables were significantly
different between the on and off stimulation states, as reported in
previous studies [53,54], thus indicating preserved rational
decision making.
Short-term modification of self-reported impulsivity
The results of the questionnaires indicated that STN-DBS is
able to affect the perception of some aspects of impulsivity in the
short term. Indeed, patients’ reports on the BIS show that they feel
more impulsive in the off stimulation condition, especially with
regard to attentional impulsivity. These findings are in apparent
contrast with previous studies suggesting that PD patients on
stimulation report higher scores of self-assessed impulsivity [18].
However, Ha¨lbig and colleagues did not compare scores on the
BIS within the same group of patients, but between one group of
patients on stimulation and another group on medication.
The results of the SPSRQ revealed a significant difference
between SP and SR scores that were independent of the condition
of stimulation, that is, patients described themselves as more
sensitive to punishment than to rewards. Of note is that PD
patients were off medication and that previous studies [62] have
shown that unmedicated PD patients are more sensitive to
negative than to positive feedbacks in procedural learning tasks.
Our results suggest that greater sensitivity to punishment may be a
general characteristic of the off medication state, not necessarily
confined to procedural learning tasks [62]. This interpretation is
further supported by the fact that, although this is the first study
using the SPSRQ to test Parkinson patients and therefore no
specific normative data are available for such population, in the
original article by Torrubia and colleagues [39], the SR and SP
scores appear to be very similar (SR: 11.98 (5.06) for women and
11.65 (5.27) for men, SP: 10.11 (4.05) for women and 12.18 (4.48)
for men), thus suggesting that, in control subjects, the two systems
are balanced.
Not all previous studies have reported short-term changes in
psychological variables when stimulation was turned off or on. For
instance, Berney and colleagues showed that depression, anxiety
and elation remained stable after acute changes in the stimulation
condition [63]. In contrast, Funkiewiez and colleagues [64]
reported that both stimulation and medication were able to
improve subjective feelings of well-being, euphoria and motiva-
tion, and to decrease anxiety and fatigue. Similarly, Amanzio and
collaborators [23] showed that lower scores of depression and
anxiety were reported by patients when psychological question-
naires were administered on medication as compared to their off
Figure 2. Results on the psychological questionnaires. Upper panel: Patients reported lower scores of impulsivity when on stimulation. AI,
attentional impulsivity; MI, motor impulsivity; NPI, non-planning impulsivity. Middle panel: patients obtained higher scores of sensitivity to
punishment than to reward independently of the condition of stimulation. SP, sensitivity to punishment; SR, sensitivity to reward. Lower panel: No
differences emerged on the QDQ; DA, delay aversion; DD, delay discounting. Please note that unlike the previous two questionnaires, higher scores
on the QDQ reflect a lower tendency to impulsivity.
doi:10.1371/journal.pone.0043261.g002
Figure 3. Correlation of delay aversion scores on the Cam-
bridge Gamble Task (CGT) and delay aversion scores on the
Quick Delay Questionnaire (QDQ) in the on stimulation
condition. A significant negative correlation was found (r =20.626
p= 0.029) suggesting that higher scores of delay aversion on the CGT
were correlated to more negative feelings when waiting for rewards.
doi:10.1371/journal.pone.0043261.g003
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medication state. Although we did not use questionnaires
specifically designed for the administration in the short time (such
as the Addiction Research Center Inventory, ARCI, [65] that was
used in [64]), we explicitly asked patients to report how they felt in
that particular condition of stimulation, thus ensuring that the
scores really reflected their feelings in the on and off stimulation
states. In addition, even if the BIS questionnaire asks to rate
behaviours retrospectively and therefore is not specifically tailored
to test the present state of mind, previous studies have shown that
its scores may be affected by different medication conditions
[66,67], thus suggesting that the perception of impulsiveness may
be affected by the therapy. The patients recruited for this study did
not stop taking non-dopaminergic therapy, which has been shown
to modulate impulsive behaviours [33]. However, it is unlikely that
such medications biased the results as we varied only the
stimulation state between conditions, thus differences in the results
are highly likely to be explained by this latter factor.
In conclusion, we provide evidence that not all impulsivities are
detrimentally affected by DBS of the STN and that the combined
use of experimental paradigms and psychological questionnaires
may be a helpful tool in reaching a convergent validity in the
evaluation of cognitive changes in PD patients. Future studies are
needed to further clarify how different subcomponents of
impulsivity can be modulated both by dopaminergic drugs and
STN-DBS. This issue is of great importance also from a clinical
standpoint, in order to understand better and reduce the risk of
post-operative suicidal behavior observed in some studies [68],
possibly related not only to depression but also to impulsive
behaviour. Altogether these findings contribute to a more general
understanding of the role that STN-DBS has in treating
behavioural abnormalities [69,70]. Future multicenter studies on
this clinically relevant issue, including larger cohorts of patients,
will allow a more precise generalization of the results.
Author Contributions
Conceived and designed the experiments: DT LC GG. Performed the
experiments: DT VV MZ ML. Analyzed the data: DT VV. Contributed
reagents/materials/analysis tools: LL. Wrote the paper: DT VV. Read and
discussed the paper: DT VV LC MZ ML LL GG.
References
1. Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, et al. (2011)
Deep brain stimulation for Parkinson disease: an expert consensus and review of
key issues. Arch Neurol 68: 165–171.
2. Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, et al. (2011) The
Movement Disorder Society Evidence-Based Medicine Review Update:
Treatments for the motor symptoms of Parkinson’s disease. Mov Disord 26:
S2–41.
3. Rodriguez-Oroz MC, Obeso JA, Lang AE, Houeto J-L, Pollak P, et al. (2005)
Bilateral deep brain stimulation in Parkinson’s disease: a multicentre study with
4 years follow-up. Brain 28: 2240–2249.
4. Volkmann J (2007) Deep brain stimulation for Parkinson’s disease. Parkinsonism
Relat Disord 13: S462–465.
5. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, et al. (1998) Electrical
stimulation of the subthalamic nucleus in advanced Parkinson’s disease.
N Engl J Med 339: 1105–1111.
6. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, et al. (2003) Five-year
follow-up of bilateral stimulation of the subthalamic nucleus in advanced
Parkinson’s disease. N Engl J Med 349: 1925–1934.
7. Dujardin K, Defebvre L, Krystkowiak P, Blond S, Deste´e A (2001) Influence of
chronic bilateral stimulation of the subthalamic nucleus on cognitive function in
Parkinson’s disease. J Neurol Sci 248: 603–611.
8. Ardouin C, Pillon B, Peiffer E, Bejjani P, Limousin P, et al. (1999) Bilateral
subthalamic or pallidal stimulation for Parkinson’s disease affects neither
memory nor executive functions: a consecutive series of 62 patients. Ann Neurol
46: 217–221.
9. Halpern C, Rick J, Danish S, Grossman M, Baltuch G (2009) Cognition
following bilateral deep brain stimulation surgery of the subthalamic nucleus for
Parkinson’s disease. Int J Geriatr Psychiatry 24: 443–451.
10. Funkiewiez A, Ardouin C, Cools R, Krack P, Fraix V, et al. (2006) Effects of
levodopa and subthalamic nucleus stimulation on cognitive and affective
functioning in Parkinson’s disease. Mov Disord 21: 1656–1662.
11. Castelli L, Rizzi L, Zibetti M, Angrisano S, Lanotte M, et al. (2010)
Neuropsychological changes 1-year after subthalamic DBS in PD patients: A
prospective controlled study. Parkinsonism Relat Disord 16: 115–118.
12. Ardouin C, Voon V, Worbe Y, Abouazar N, Czernecki V, et al. (2006)
Pathological gambling in Parkinson’s disease improves on chronic subthalamic
nucleus stimulation. Mov Disord 21: 1941–1946.
13. Bandini F, Primavera A, Pizzorno M, Cocito L (2007) Using STN DBS and
medication reduction as a strategy to treat pathological gambling in Parkinson’s
disease. Parkinsonism Relat Disord 13: 369–371.
14. Knobel D, Aybek S, Pollo C, Vingerhoets F, Berney A (2008) Rapid resolution
of dopamine dysregulation syndrome (DDS) after subthalamic DBS for
Parkinson disease (PD): a case report. Cog Behav Neurol 21: 187–189.
15. Lim SY, O’Sullivan SS, Kotschet K, Gallagher DA, Lacey C, et al. (2009)
Dopamine dysregulation syndrome, impulse control disorders and punding after
deep brain stimulation surgery for Parkinson’s disease. J Clin Neurosci 16: 1148–
1152.
16. Witjas T, Baunez C, Henry JM, Delfini M, Regis J, et al. (2005) Addiction in
Parkinson’s disease: impact of subthalamic nucleus deep brain stimulation. Mov
Disord 20: 1052–1055.
17. Lhommee E, Klinger H, Thobois S, Schmitt E, Ardouin C, et al. (2012)
Subthalamic stimulation in Parkinson’s disease: restoring the balance of
motivated behaviours. Brain 135: 1463–1477.
18. Ha¨lbig T, Tse W, Frisina P, Baker B, Hollander E, et al. (2009) Subthalamic
deep brain stimulation and impulse control in Parkinson’s disease. Eur J Neurol
16: 493–497.
19. Smeding HM, Goudriaan AE, Foncke EM, Schuurman PR, Speelman JD, et al.
(2007) Pathological gambling after bilateral subthalamic nucleus stimulation in
Parkinson disease. J Neurol Neurosurg Psychiatry 78: 517–519.
20. Broen M, Duits A, Visser-Vandewalle V, Temel Y, Winogrodzka A (2011)
Impulse control and related disorders in Parkinson’s disease patients treated with
bilateral subthalamic nucleus stimulation: a review. Parkinsonism Relat Disord
17: 413–417.
21. Antonelli F, Ray N, Strafella AP (2011) Impulsivity and Parkinson’s disease:
more than just disinhibition. J Neurol Sci 310: 202–207.
22. Robert G, Drapier D, Verin M, Millet B, Azulay JP, et al. (2009) Cognitive
impulsivity in Parkinson’s disease patients: assessment and pathophysiology.
Mov Disord 24: 2316–2327.
23. Amanzio M, Monteverdi S, Giordano A, Soliveri P, Filippi P, et al. (2010)
Impaired awareness of movement disorders in Parkinson’s disease. Brain Cogn
72: 337–346.
24. Amanzio M, Torta DM (2011) Unawareness of movement disorders in
Parkinson’s disease. In: Movement disorders: Causes, Diagnoses and Treat-
ments. Editors: Barbara J. Larsen Nova Science Publishers, Inc.
25. Ballanger B, van Eimeren T, Moro E, Lozano AM, Hamani C, et al. (2009)
Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann
Neurol 66: 817–824.
26. Hershey T, Revilla FJ, Wernle A, Gibson PS, Dowling JL, et al. (2004)
Stimulation of STN impairs aspects of cognitive control in PD. Neurology 62:
1110–1114.
27. Campbell MC, Karimi M, Weaver PM, Wu J, Perantie DC, et al. (2008) Neural
correlates of STN DBS-induced cognitive variability in Parkinson disease.
Neuropsychologia 46: 3162–3169.
28. Ray NJ, Jenkinson N, Brittain J, Holland P, Joint C, et al. (2009) The role of the
subthalamic nucleus in response inhibition: evidence from deep brain
stimulation for Parkinson’s disease. Neuropsychologia 47: 2828–2834.
29. Frank MJ, Samanta J, Moustafa AA, Sherman SJ (2007) Hold your horses:
impulsivity, deep brain stimulation, and medication in parkinsonism. Science
318: 1309–1312.
30. Cavanagh JF, Wiecki TV, Cohen MX, Figueroa CM, Samanta J, et al. (2011)
Subthalamic nucleus stimulation reverses mediofrontal influence over decision
threshold. Nat Neurosci 14: 1462–1467.
31. Wylie SA, Ridderinkhof KR, Elias WJ, Frysinger RC, Bashore TR, et al. (2010)
Subthalamic nucleus stimulation influences expression and suppression of
impulsive behaviour in Parkinson’s disease. Brain 133: 3611–3624.
32. Chamberlain S, Sahakian B (2007) The neuropsychiatry of impulsivity. Curr
Opin Psychiatry 20: 255–261.
33. Pattij T, Vanderschuren L (2008) The neuropharmacology of impulsive
behaviour. Trends Pharmacol Sci 29: 192–199.
34. Evenden J (1999) Varieties of impulsivity. Psychopharmachology (Berl) 146:
348–361.
35. Witt K, Pulkowski U, Herzog J, Lorenz D, Hamel W, et al. (2004) Deep brain
stimulation of the subthalamic nucleus improves cognitive flexibility but impairs
response inhibition in Parkinson disease. Arch Neurol 61: 697–700.
36. Winstanley CA, Baunez C, Theobald DE, Robbins TW (2005) Lesions to the
subthalamic nucleus decrease impulsive choice but impair autoshaping in rats:
Delay Aversion, DBS and PD
PLOS ONE | www.plosone.org 7 September 2012 | Volume 7 | Issue 9 | e43261
the importance of the basal ganglia in Pavlovian conditioning and impulse
control. Eur J Neurosci 21: 3107–3116.
37. Rogers RD, Everitt B, Baldacchino A, Blackshaw A, Swainson R, et al. (1999)
Dissociable deficits in the decision-making cognition of chronic amphetamine
abusers, opiate abusers, patients with focal damage to prefrontal cortex, and
tryptophan-depleted normal volunteers; evidence for monoaminergic mecha-
nism. Neuropsychopharmacology 20: 322–339.
38. Fossati A, Di Ceglie A, Acquarini E, Barratt ES (2001) Psychometric properties
of an Italian version of the Barratt Impulsiveness Scale-11 (BIS-11) in nonclinical
subjects. J Clin Psychol 57: 815–828.
39. Torrubia R, Avila C, Molto J, Caseras X (2001) The Sensitivity to Punishment
and Sensitivity to Reward Questionnaire (SPSRQ) as a measure of Gray’s
anxiety and impulsivity dimensions. Pers Individ Diff 31: 837–862.
40. Clare S, Helps S, Sonuga-Barke EJ (2010) The quick delay questionnaire: a
measure of delay aversion and discounting in adults. Atten Defic and Hyperac
Disord 2: 43–48.
41. Gray JA (1981) A critique of Eysenck’s theory of personality, In H.J. Eysenck
(Ed.) A model for personality 246–276.
42. Gray JA (1982) The neuropsychology of anxiety: An enquiry into the functions
of the septo-hippocampal system. Oxford University Press.
43. Grafen A, Hails R (2002) Modern statistics for the life sciences. Oxford
University Press.
44. Uslaner J, Robinson T (2006) Subthalamic nucleus lesions increase impulsive
action and decrease impulsive choice - mediation by enhanced incentive
motivation? Eur J Neurosci 24: 2345–2354.
45. Winstanley CA, Dalley JW, Theobald DE, Robbins TW (2004) Fractionating
impulsivity: contrasting effects of central 5-HT depletion on different measures
of impulsive behavior. Neuropsychopharmacology 29: 1331–1343.
46. Hershey T, Revilla F, Wernle A, Schneider Gibson P, Dowling J, et al. (2004)
Stimulation of STN impairs aspects of cognitive control in PD. Neurology 62:
1110–1114.
47. Hershey T, Campbell MC, Videen TO, Lugar HM, Weaver PM, et al. (2010)
Mapping Go-No-Go performance within the subthalamic nucleus region. Brain
133: 3625–3634.
48. Frank M, Samanta J, Moustafa A, Sherman S (2007) Hold your horses:
impulsivity, deep brain stimulation, and medication in Parkinsonism. Science
318: 1309–1312.
49. Aron AR, Behrens TE, Smith S, Frank MJ, Poldrack RA (2007) Triangulating a
cognitive control network using diffusion-weighted magnetic resonance imaging
(MRI) and functional MRI. J Neurosci 27: 3743–3752.
50. Inase M, Tokuno H, Nambu A, Akazawa T, Takada M (1999) Corticostriatal
and corticosubthalamic input zones from the presupplementary motor area in
the macaque monkey: comparison with the input zones from the supplementary
motor area. Brain Res 833: 191–201.
51. Nambu A, Tokuno H, Takada M (2002) Functional significance of the cortico-
subthalamo-pallidal ‘hyperdirect’ pathway. Neurosci Res 43: 111–117.
52. Rodriguez-Oroz MC, Lopez-Azcarate J, Garcia-Garcia D, Alegre M, Toledo J,
et al. (2012) Involvement of the subthalamic nucleus in impulse control disorders
associated with Parkinson’s disease. Brain 134: 36–49.
53. Cools R, Barker RA, Sahakian B, Robbins T (2003) L-Dopa medication
remediates cognitive inflexibility, but increases impulsivity in patients with
Parkinson’s disease. Neuropsychologia 4: 1431–1441.
54. Torta DM, Castelli L, Zibetti M, Lopiano L, Geminiani G (2009) On the role of
dopamine replacement therapy in decision-making, working memory, and
reward in Parkinson’s disease: does the therapy-dose matter? Brain Cogn 71:
84–91.
55. Torta DM, Castelli L, Latini-Corazzini L, Banche A, Lopiano L, et al. (2010)
Dissociation between time reproduction of actions and of intervals in patients
with Parkinson’s disease. J Neurol 257: 1356–1361.
56. Gotham A, Brownm R, Marsden C (1988) ‘Frontal’ cognitive function in
patients with Parkinson’s disease ‘on’ and ‘off’ levodopa. Brain 111: 299–321.
57. Swainson R, Rogers R, Sahakian B, Summers B, Polkey C, et al. (2000)
Probabilistic learning and reversal deficits in patients with Parkinson’s disease or
frontal or temporal lobe lesions: possible adverse effects of dopaminergic
medication. Neuropsychologia 38: 596–612.
58. Housden CR, O’Sullivan SS, Joyce EM, Lees AJ, Roiser JP (2010) Intact reward
learning but elevated delay discounting in Parkinson’s disease patients with
impulsive-compulsive spectrum behaviors. Neuropsychopharmacology 35:
2155–2164.
59. Meck W, Penney T, Pouthas V (2008) Cortico-striatal representation of time in
animals and humans. Curr Opin Neurobiol 18: 145–152.
60. Merchant H, Luciana M, Hooper C, Majestic S, Tuite P (2008) Interval timing
and Parkinon’s disease: heterogeneity in temporal performances. Exp Brain Res
184: 233–248.
61. Wild-Wall N, Willemssen R, Falkenstein M, Beste C (2008) Time estimation in
healthy ageing and neurodegenerative basal ganglia disorders. Neurosci Lett
442: 34–38.
62. Frank MJ, Seeberger LC, O’Reilly R C (2004) By carrot or by stick: cognitive
reinforcement learning in parkinsonism. Science 306: 1940–1943.
63. Berney A, Panisset M, Sadikot A, Ptito A, Dagher A, et al. (2007) Mood stability
during acute stimulator challenge in Parkinson’s disease patients under long-
term treatment with subthalamic deep brain stimulation. Mov Disord 22: 1093–
1096.
64. Funkiewiez A, Ardouin C, Krack P, Fraix V, Van Blercom N, et al. (2003) Acute
psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in
Parkinson’s disease. Mov Disord 18: 524–530.
65. Haertzen CA, Hill HE, Belleville RE (1963) Development of the Addiction
Research Center Inventory (ARCI): selection of items that are sensitive to the
effects of various drugs. Psychopharmacology 4: 155–166.
66. Berlin HA, Braun A, Simeon D, Koran LM, Potenza MN, et al. (in press) A
double-blind, placebo-controlled trial of topiramate for pathological gambling.
World J Biol Psychiatry doi:10.3109/15622975.2011.560964.
67. Bermejo PE, Ruiz-Huete C, Anciones B (2010) Zonisamide in managing impulse
control disorders in Parkinson’s disease. J Neurol 257: 1682–1685.
68. Voon V, Krack P, Lang AE, Lozano AM, Dujardin K, et al. (2008) A
multicentre study on suicide outcomes following subthalamic stimulation for
Parkinson’s disease. Brain 131: 2720–2728.
69. Chabardes S, Polosan M, Krack P, Bastin J, Krainik A, et al. (in press) Deep
Brain Stimulation for Obsessive-Compulsive Disorder: Subthalamic Nucleus
Target. World Neurosurg doi:10.1016/j.wneu.2012.03.010.
70. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, et al. (2005)
Deep brain stimulation for treatment-resistant depression. Neuron 45: 651–660.
Delay Aversion, DBS and PD
PLOS ONE | www.plosone.org 8 September 2012 | Volume 7 | Issue 9 | e43261
